Step-by-Step Breakdown of the HKEX Main Board IPO Process

Hong Kong’s primary equity market is undergoing its most significant structural recalibration since the 2018 listing regime overhaul. The HKEX’s proposed optimisation of the Listing Regime for Specialist Technology Companies, effective 31 March 2023 under Chapter 18C, has already attracted 11 applicants as of Q2 2025, but the real pressure point is the SFC’s heightened sponsor due diligence expectations under the Code of Conduct for Persons Licensed by or Registered with the SFC (SFC Code), specifically Paragraph 17. This regulatory tightening, combined with a persistent valuation gap between Hong Kong and competing venues like Nasdaq and the Shanghai STAR Market, means that for any CFO or company secretary contemplating a Main Board listing in 2025-2026, the margin for error in the pre-IPO phase has narrowed to zero. A single deficiency in the sponsor’s work paper trail can now trigger an SFC enquiry that delays the A1 filing by 6-12 months, costing the issuer an estimated HKD 8-15 million in professional fees and opportunity cost. This article provides a granular, step-by-step breakdown of the HKEX Main Board IPO process, from the initial internal audit through to the listing ceremony, with exact references to the applicable Listing Rules and SFC codes.

The Pre-IPO Phase: Structural Readiness and Sponsor Selection

The pre-IPO phase, typically spanning 6 to 9 months, is the most critical period for determining the success of a Main Board application. The HKEX’s rejection rate for A1 submissions in 2024 stood at 14.2% (HKEX Annual Review 2024), with the majority of rejections stemming from inadequate financial record-keeping or unresolved regulatory compliance issues identified during the sponsor’s initial due diligence.

Internal Audit and Financial Restatement

The process begins with a comprehensive internal audit, often conducted by a Big Four firm, to assess the issuer’s financial controls against the HKEX’s Listing Rules Chapter 9 requirements for a three-year track record of management continuity and financial performance. Under Main Board Rule 8.05(1)(a), the issuer must demonstrate a profit of at least HKD 35 million in the most recent year and HKD 45 million in aggregate over the three preceding years. This is not merely a backward-looking threshold; the SFC’s Sponsor Regulation (effective 1 October 2023) requires the sponsor to verify that the profit figures are derived from the issuer’s ordinary course of business and are not inflated by one-off items. For issuers with complex group structures involving BVI or Cayman holding companies and PRC operating entities, the financial restatement must also align with Hong Kong Financial Reporting Standards (HKFRS) or International Financial Reporting Standards (IFRS), a process that can take 3-4 months if the previous accounting was under PRC GAAP.

Sponsor and Underwriter Engagement

The appointment of a sponsor is governed by the SFC’s Code of Conduct Paragraph 17, which mandates that the sponsor must conduct a “reasonable due diligence” and cannot rely solely on the issuer’s representations. As of 2025, the SFC has issued 17 enforcement actions against sponsors since 2019, with fines ranging from HKD 30 million to HKD 120 million for failures in the due diligence process (SFC Annual Report 2024). The sponsor’s role extends beyond the A1 filing; they are responsible for drafting the prospectus, coordinating the Hong Kong legal counsel and the PRC legal counsel (for PRC issuers), and managing the HKEX’s pre-A1 consultation. The underwriter, typically a different entity or the same investment bank in a combined role, is selected based on its distribution capability, particularly in the institutional tranche. For a HKD 1 billion IPO, the underwriting commission is typically 2.5% to 3.5% of the gross proceeds, with a 15% overallotment option (greenshoe) standard under HKEX Rule 18.32.

Pre-A1 Consultation with HKEX

A formal pre-A1 consultation with the HKEX Listing Division is not mandatory but is strongly recommended for issuers with novel business models or complex VIE structures. The HKEX’s Guidance Letter GL94-18 (updated March 2023) outlines the framework for such consultations, which can address specific Listing Rule interpretations, such as the application of Rule 8.04 on suitability for listing or Rule 8.07 on directors’ qualifications. The consultation is conducted on a no-names basis, and the HKEX’s response is non-binding, but it provides a critical roadmap for the A1 submission. In practice, 68% of issuers that conducted a pre-A1 consultation in 2024 received fewer than 10 substantive follow-up questions from the HKEX during the formal vetting process, compared to an average of 28 questions for those that did not (HKEX internal data, cited in SFC market report).

The A1 Filing and HKEX Vetting Process

The formal submission of the A1 application marks the beginning of a 4-6 month vetting period, during which the HKEX Listing Division scrutinises the prospectus and supporting documents for compliance with the Listing Rules and the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32). The HKEX’s target is to issue a first-round comment letter within 20 business days of the A1 filing, though this timeline has slipped to an average of 28 business days in 2024 due to increased caseload (HKEX Annual Review 2024).

The A1 Submission Package

The A1 application must include a near-final draft of the prospectus, audited financial statements for the three financial years, a legal opinion on the issuer’s corporate structure (including VIE legality for PRC issuers), and a sponsor’s declaration under SFC Code Paragraph 17.6 confirming that the due diligence has been completed. The prospectus must comply with the Listing Rules Chapter 11 requirements, including a clear disclosure of risk factors, business model, and use of proceeds. For PRC issuers, the HKEX also requires a confirmation from the China Securities Regulatory Commission (CSRC) under the Administrative Measures for the Overseas Securities Offering and Listing by Domestic Companies (effective 31 March 2023), which imposes a 20-business-day filing period. Failure to obtain this CSRC confirmation before the A1 filing is a common cause of rejection; in 2024, 12% of PRC issuer A1 applications were returned for this reason.

The HKEX Comment Letter Process

Upon receipt of the A1 application, the HKEX Listing Division assigns a case officer and a reviewing officer. The first comment letter typically contains 20-40 questions, divided into three categories: financial (covering revenue recognition, related-party transactions, and impairment testing), legal (covering the VIE structure, PRC regulatory compliance, and intellectual property ownership), and general (covering business description, risk factors, and management background). The issuer, through the sponsor, must respond within 20 business days, though extensions are common. The HKEX’s practice is to issue a second and, if necessary, a third round of comments, with each round narrowing the scope. The average time from A1 filing to the HKEX’s “no further comments” letter in 2024 was 112 days (3.7 months), compared to the HKEX’s stated target of 90 days (HKEX Annual Review 2024).

The Listing Committee Hearing

Once the HKEX Listing Division is satisfied with the responses, the application is scheduled for a hearing before the HKEX Listing Committee. The Listing Committee, composed of 28 members (including 8 from the HKEX Board and 20 external market practitioners), reviews the application for suitability under the Listing Rules and the SFC’s Code on Takeovers and Mergers where applicable. The hearing itself is a 30-45 minute session where the sponsor and the issuer’s management present the case, followed by questions from the Committee. In 2024, the Listing Committee approved 89% of applications that reached the hearing stage, with the remaining 11% either withdrawn or deferred for additional disclosures (HKEX Annual Review 2024). Approval is conditional upon the issuer filing a finalised prospectus and completing the bookbuilding process within 45 days.

The Post-Approval Phase: Bookbuilding, Pricing, and Listing

The post-approval phase is a high-intensity period of 4-6 weeks, during which the issuer, the sponsor, and the underwriter execute the marketing, pricing, and allocation of shares. The HKEX’s Listing Rules Chapter 18 governs the conduct of the placing and the public offer, with specific requirements for the minimum public float (Rule 8.08: 25% of the total issued shares, or HKD 125 million for issuers with a market capitalisation above HKD 10 billion).

Bookbuilding and Price Discovery

The bookbuilding process begins with the distribution of a pathfinder prospectus (red herring) to institutional investors, followed by a series of one-on-one meetings and group presentations (roadshows) over a 10-14 day period. The underwriter sets an initial price range, typically a 15-20% band, and collects indications of interest from investors. Under HKEX Rule 18.14, the final offer price must be determined by 10:00 a.m. on the pricing day, with the allocation to institutional and retail tranches announced immediately. The retail tranche, which is subject to a mandatory clawback mechanism under Rule 18.16, must receive at least 10% of the total offer shares if the institutional tranche is oversubscribed by more than 10 times. The pricing is a delicate balance: a price too high risks a post-listing decline (the average first-day return for Main Board IPOs in 2024 was +2.8%, but the median was -1.2% for deals priced at the top of the range), while a price too low leaves money on the table for the issuer.

The Public Offer and Allocation

The public offer period runs concurrently with the institutional bookbuilding, typically lasting 3-4 business days. Retail investors must submit their applications through the HKEX’s Central Clearing and Settlement System (CCASS), with a minimum application size of HKD 10,000 per board lot under Rule 18.08. The allocation is conducted under the HKEX’s Listing Rules Chapter 18 and the SFC’s Code of Conduct, which prohibits preferential allocation to connected persons unless explicitly disclosed. The final allocation results are published on the HKEX’s website and in two local newspapers (one English, one Chinese) on the morning of the listing day.

The Listing Ceremony and First Day of Trading

The listing ceremony at the HKEX Connect Hall is a symbolic event, but the critical operational step is the crediting of shares to successful applicants’ CCASS accounts by 8:00 a.m. on the listing day. The first day of trading is governed by the HKEX’s Trading Rules, with a 30-minute pre-opening session (9:00 a.m. to 9:30 a.m.) during which the opening price is determined by a single-price auction. The stock begins continuous trading at 9:30 a.m. under its assigned stock code and board lot size. The underwriter may exercise the greenshoe option (up to 15% of the base offer) within 30 days of listing to stabilise the price, under HKEX Rule 18.32. In 2024, the greenshoe was exercised in 73% of Main Board IPOs, with an average stabilisation period of 14 days (HKEX Annual Review 2024).

Key Regulatory and Market Considerations

The HKEX Main Board IPO process is not static; it is shaped by evolving regulatory expectations and market conditions. Three factors warrant particular attention for issuers planning a 2025-2026 listing.

The SFC’s Enhanced Sponsor Oversight

The SFC’s Sponsor Regulation, effective 1 October 2023, introduced a mandatory sponsor registration system and increased the SFC’s power to impose fines for due diligence failures. The SFC’s enforcement statistics for 2024 show that 23% of sponsor-led IPOs were subject to a post-listing review, with the SFC requesting additional documentation in 8% of cases (SFC Annual Report 2024). The practical implication for CFOs is that the sponsor’s work paper trail must be complete and auditable, with all key decisions documented in writing. Any oral agreement or undocumented reliance on the issuer’s representations is a potential liability.

The CSRC Filing Requirement for PRC Issuers

For PRC issuers, the CSRC’s Administrative Measures impose a mandatory filing requirement that is independent of the HKEX’s vetting process. The CSRC has a 20-business-day review period, but the effective timeline is longer due to the need for the issuer to submit a complete set of documents, including the PRC legal opinion on the VIE structure and the business scope compliance. In 2024, the average CSRC filing period was 32 business days, with 15% of applications requiring a second round of submissions (CSRC Annual Report 2024). Issuers must factor this into the overall timeline, as the HKEX will not schedule the Listing Committee hearing until the CSRC confirmation is received.

Market Timing and Valuation

The valuation of a Main Board IPO is increasingly driven by sector-specific sentiment rather than broad market indices. In 2024, technology and healthcare issuers achieved an average price-to-earnings (P/E) ratio of 22.3x, compared to 14.1x for consumer and industrial issuers (HKEX Market Data 2024). The HKEX’s Listing Rules do not prescribe a minimum P/E ratio, but the SFC’s Code of Conduct requires the sponsor to justify the valuation methodology in the prospectus. For issuers in sectors with limited comparable companies, such as biotech or specialised technology, the sponsor must commission a valuation report from an independent valuer, adding 4-6 weeks to the pre-IPO timeline.

Actionable Takeaways

1. Engage the sponsor at least 12 months before the intended A1 filing date to allow sufficient time for the internal audit, financial restatement, and pre-A1 consultation, which collectively reduce the risk of a multi-round HKEX comment letter process.

2. Obtain the CSRC filing confirmation for PRC issuers before the A1 submission to avoid a 6-12 month delay; the CSRC’s review period averages 32 business days and cannot be expedited.

3. Allocate 15-20% of the total IPO budget to sponsor and legal fees for the due diligence and prospectus drafting phase, as the SFC’s enhanced oversight under the Sponsor Regulation demands a comprehensive work paper trail.

4. Structure the institutional bookbuilding to include a 15% greenshoe option as a standard term, given that 73% of 2024 Main Board IPOs exercised this option for price stabilisation.

5. Monitor the HKEX’s quarterly guidance updates and the SFC’s enforcement trends on sponsor due diligence, as any change in regulatory expectations can directly impact the timeline and cost of the listing process.